---
title: 丹麦生物技术公司鼓励西方制药公司挖掘中国令人印象深刻的创新能力
date: 2024-05-14T04:00:45.369Z
description: Genmab argues ‘anti-Chinese sentiment’ should not deter dealmaking
tag: 

- Tag world
author: ft
---

[原文链接](https://ft.com/content/2f3caeee-ff64-47eb-b00e-6568ad1f1858)

# 丹麦生物技术公司鼓励西方制药公司挖掘中国令人印象深刻的创新能力

作为一家领先的欧洲生物技术公司，**Genmab** 鼓励西方制药公司参与中国蓬勃发展的生命科学行业，尽管美国存在“反华情绪”。**Jan van de Winkel**，这家丹麦生物技术巨头的 CEO，强调了与中国生物技术公司建立合作关系的重要性，并重点介绍了中国政府在这一领域的大量投资和快速增长。这种观点也反映在阿斯利康和GSK 最近的收购和交易中，这表明了中国在创新和定价方面的吸引力。

范·德·温克尔（Van de Winkel）提请注意中国在生物技术和生命科学领域取得的类似工业革命的进步，并敦促公司抓住这一新兴市场带来的机遇。然而，他也承认在知识产权方面存在的担忧，并计划通过将部分业务迁出中国来“减轻风险”。

Genmab 最近收购了**ProfoundBio**（一家总部位于中国和美国的公司），这表明了它对利用中国创新的承诺。这项交易使 Genmab 的产品组合增加了有前景的卵巢癌治疗方法，并增强了它在**抗体药物偶联物（ADCs）**方面的能力，这是一种先进的化疗形式。尽管 ADC 领域竞争激烈，全球投资显著，但 Genmab 与大型制药公司的合作伙伴关系及其强大的财务状况使其能够保持独立和盈利。

尽管与强生公司存在法律纠纷，并且在股市表现方面面临挑战，但 Genmab 的成功证明了欧洲生物技术公司可以通过战略合作伙伴关系和接触美国投资者而繁荣发展的潜力。

---

# Danish biotech encourages companies to tap into China's 'impressive innovation' 

Genmab, a leading European biotech company, encourages Western pharmaceutical firms to engage with China's rapidly growing life sciences sector, despite "anti-Chinese sentiment" in the US. **Jan van de Winkel**, CEO of the Danish biotech behemoth, emphasizes the importance of partnering with Chinese biotechs, highlighting the country's massive government investments and rapid growth. This sentiment is reflected in recent acquisitions and deals by AstraZeneca and GSK, showcasing the appeal of Chinese innovation and pricing. 

Van de Winkel draws attention to the industrial revolution-like advancements in China's biotech and life sciences sectors, urging companies to embrace the opportunities presented by this emerging market. However, he also acknowledges the intellectual property concerns, planning to "de-risk" by moving some operations outside of China. 

Genmab's recent acquisition of ProfoundBio, a company based in both China and the US, demonstrates its commitment to tapping into Chinese innovation. The deal expands Genmab's portfolio with a promising ovarian cancer treatment and enhances its capabilities in **antibody drug conjugates (ADCs)**, an advanced form of chemotherapy. While the ADC field is highly competitive, with significant global investments, Genmab's partnerships with major pharmaceutical companies and its strong financial position have allowed it to remain independent and profitable. 

Despite legal setbacks with J&J and stock performance challenges, Genmab's success showcases the potential for European biotech companies to thrive through strategic partnerships and access to US investors.

[Source Link](https://ft.com/content/2f3caeee-ff64-47eb-b00e-6568ad1f1858)

